Norway
· Delayed Price · Currency is NOK BerGenBio ASA Company Description
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway.
The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC).
It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.
BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
| Country | Norway |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Martin Olin |
Contact Details
Address: MOellendalsbakken 9 Bergen, 5009 Norway | |
| Phone | 47 55 96 11 59 |
| Website | bergenbio.com |
Stock Details
| Ticker Symbol | BGBIO |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010650013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Martin Olin | Chief Executive Officer |
| Rune Skeie | Chief Financial Officer |
| Cristina Oliva M.D. | Chief Medical Officer |
| Graham Morell | Head of IR |
| Gayle M. Mills M.B.A | Chief Business Officer |
| Dr. Akil Jackson | Medical Director |